Julien Le Guyader, © 大成 Dentons

大成 Dentons: All about taxes

大成 Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of 大成 Dentons since 2014.

Trained as a tax specialist, he regularly advises healthcare companies but also major international groups on legal, tax and regulatory structuring issues. Le Guyader was formerly at Simmons & Simmons LLP, Ernst & Young Société d’Avocats and operated as Tax Director of the LEEM. He started his career at Laboratoires BOIRON as group tax specialist in charge of transfer prices. Le Guyader graduated from the ESC Lille and the University Paris I – Panthéon Sorbonne in Business and Tax Law, Public Law and Economics. He is also member of the Pharma Licensing Club France and administrator of the Association des Cadres de l’Industrie Pharmaceutique (ACIP).

Gerd Zettlmeissl, © TuBerculosis Vaccine Initiative

Asit biotech: Expertise in vaccines

Belgian clinical-stage immunotherapy developer  Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011. 

Before joining Asit biotech, he was CEO of Austrian company Intercell AG – which in 2013 merged with French company Vivalis create European vaccine and antibody leader Valneva. Zettlmeissl holds a doctoral degree in biochemistry from the University of Regensburg in Germany and did a post-doctoral fellowship in virology at the Institut Pasteur in Paris. Since 1985, Zettlmeissl has held various R&D and managerial positions at a number of international pharmaceutical companies, among others Managing Director of German vaccine company Chiron Behring.

In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Zettlmeissl currently serves as non-executive director of Aeras, (USA). Until early 2015, he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline.

Erstwhile Asit biotech Chairman Béatrice De Vos has stepped down “to focus on new projects”.  

Alain Dostie, @ Nanobiotix

Nanobiotix: Oncology expert

The nanomedicine specialist Nanobiotix announced ex-Novartis industry veteran Alain Dostie as new Chief Operating Officer. 

Dostie will be in charge of Nano­biotix’ operations, including development, manufacturing, market access, and sales, particularly for the lead product NBTXR3. The radio-enhancer could reach a CE market approval and a first phase II/III interim readout this year. Dostie, who holds a Bachelor of Science in Human Biology, joins the company after 25 years of international experience in the  pharmaceutical industry, especially in market access and oncology. Previously, he worked as Oncology General Manager at Novartis Pharma GmbH in Germany.

Walid Abi-Saab, @ Galapagos

Galapagos: To the clinic

Mechelen-based biotech Galapagos NV has appointed Walid Abi-Saab to the role of Chief Medical Officer. 

Abi-Saab joins from Shire Pharmaceuticals, where he held various clinical development leadership positions, most recently Group Vice President, Global Clinical Development - Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. Before Shire, the trained psychiatrist led the clinical development activities at Novartis, Abbott Laboratories, and Pfizer.

Maria Carell, @ Pharmalink

Pharmalink: Global chair

Specialty pharma company Pharmalink AB has elected Maria Carell as Chair of the Board of Directors. Carell replaces Hilde Furberg, who will take over as Vice Chair. 

Carell previously held the position of  CEO of Exeltis USA Inc. Before that, she was president of Meda US. Before joining Meda, she served as President and CEO of medtech company Q-Med AB, and spent more than four years working as General Manager at Actavis Pharmaceuticals in the Nordic region.

Howard Fillit, © Oryzon

Oryzon Genomics: Alzheimer aid

Barcelona-based epigenetics specialist Oryzon Genomics has made new additions to its Scientific Advisory Board in order to be prepared for the completion of its Phase I trial for dementia drug ORY-2001. Renowned Alzheimer’s disease expert Howard Fillit will take over a seat on the board.

Fillit is the Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. He is also a clinical professor of geriatric medicine and palliative care, medicine, and neurosciences at The Icahn School of Medicine at Mount Sinai Medical Center, New York. Fillit has held faculty positions at Rockefeller University, SUNY-Stony Brook School of Medicine, and Cornell University School of Medicine,  and has more than 300 scientific publications to his name. Together with Fillit, neurologist José Luis Molinuevo, Scientific Director of the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation, will also join Oryzon’s ­Scientific Advisory Board.